Bicycle Therapeutics Plc ADR Dossier
Qualitative Analysis
Business overview
Bicycle Therapeutics plc is a clinical-stage pharmaceutical company pioneering a novel and differentiated class of medicines referred to as Bicycle® molecules. These molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This unique constraint facilitates target binding with high affinity and selectivity, combining the pharmacology of a biologic with the manufacturing and pharmacokinetic advantages of a small molecule. The company's proprietary phage-display screening platform, founded on the Nobel Prize-winning science of Sir Greg Winter, is used to identify these Bicycles. Bicycle's pipeline is primarily focused on oncology and radiopharmaceuticals, including Bicycle Drug Conjugates (BDCs) and Bicycle Radioconjugates (BRCs).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Initiated a strategic refocus in March 2026 to prioritize resources on promising next-generation therapeutics, including BT5528 (nuzefatide pevedotin) and the wholly owned Bicycle Radioconjugate (BRC) pipeline. As part of this, the company closed enrollment for Duravelo-3 and Duravelo-4 trials, converted Duravelo-2 to a randomized Phase 2 trial, and proposed a 30% workforce reduction.
Expected impact: Expected to reduce annual operating expenses by approximately 50% and extend the company's cash runway by approximately two years into 2030.
Establishing a comprehensive, end-to-end supply chain ecosystem to support the discovery, development, and commercial supply of its wholly owned portfolio of Lead-212 (212Pb) Targeted Alpha Therapy (TAT) radiopharmaceuticals.
Expected impact: Secures long-term access to reprocessed uranium and thorium-228 extraction capabilities, enabling the potential production of tens of thousands of doses of 212Pb annually.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides Bicycle Therapeutics with access to up to 400 tonnes of reprocessed uranium (RepU) over a 15-year period, serving as a sustainable source for regenerating Thorium-228 and Lead-212 for Targeted Alpha Therapies.
Terms: 15-year contract with an option to renew; specific financial terms not disclosed.
Collaborating to scale up the extraction of Thorium-228 (228Th) from the reprocessed uranium obtained from the NDA, which is the critical precursor for generating Lead-212.
Terms: Collaborative development terms; specific financial figures not disclosed.
Developing a bespoke, wholly owned Lead-212 (212Pb) generator exclusively for Bicycle Therapeutics to process extracted isotopes into therapeutic payloads.
Terms: Exclusive development agreement; initial quantities of 212Pb successfully produced.
Comprehensive partnership established in February 2025 for the supply of various radioisotopes and the contract development and manufacturing (CDMO) of Bicycle Radio Conjugates (BRC molecules) at their GMP facility in Berlin.
Terms: Long-term supply and manufacturing agreement; specific financial terms not disclosed.